血管紧张素转换酶抑制药/血管紧张素受体阻滞药联合钙通道阻滞剂单片复方制剂治疗原发性高血压中国专家共识

2022-07-15 中国医师协会高血压专业委员会 中华高血压杂志

《中国心血管健康与疾病报告2019》调查结果显示,我国高血压患病率达2.45亿,高血压患病率总体仍呈上升趋势

中文标题:

血管紧张素转换酶抑制药/血管紧张素受体阻滞药联合钙通道阻滞剂单片复方制剂治疗原发性高血压中国专家共识

发布日期:

2022-07-15

简要介绍:

《中国心血管健康与疾病报告2019》调查结果显示,我国高血压患病率达2.45亿,高血压患病率总体仍呈上升趋势[1],18岁以上人群高血压知晓率、治疗率和控制率分别为51.6%、45.8%和16.8%[2],我国高血压防控形势依然严峻。起始联合治疗原发性高血压具有降压效果好、安全性高等优势,是降压治疗的基本原则之一[3]

相关资料下载:
[AttachmentFileName(sort=1, fileName=血管紧张素转换酶抑制药_血管紧张素受体阻滞药联合钙通道阻滞剂单片复方制剂治疗原发性高血压中国专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=e1d471c00256e76b, title=血管紧张素转换酶抑制药/血管紧张素受体阻滞药联合钙通道阻滞剂单片复方制剂治疗原发性高血压中国专家共识, enTitle=, guiderFrom=中华高血压杂志, authorId=0, author=, summary=《中国心血管健康与疾病报告2019》调查结果显示,我国高血压患病率达2.45亿,高血压患病率总体仍呈上升趋势, cover=https://img.medsci.cn/20220805/1659666861502_5579292.jpg, journalId=0, articlesId=null, associationId=677, associationName=中国医师协会高血压专业委员会, associationIntro=null, copyright=0, guiderPublishedTime=Fri Jul 15 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">《中国心血管健康与疾病报告2019》调查结果显示,我国高血压患病率达2.45亿,高血压患病率总体仍呈上升趋势</span><sup style="color: #666666;">[1]</sup><span style="color: #666666;">,18岁以上人群高血压知晓率、治疗率和控制率分别为51.6%、45.8%和16.8%</span><sup style="color: #666666;">[2]</sup><span style="color: #666666;">,我国高血压防控形势依然严峻。起始联合治疗原发性高血压具有降压效果好、安全性高等优势,是降压治疗的基本原则之一</span><sup style="color: #666666;">[3]</sup><span style="color: #666666;">。</span></p>, tagList=[TagDto(tagId=9068, tagName=原发性高血压), TagDto(tagId=457897, tagName=血管紧张素转换酶抑制药)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2219, appHits=152, showAppHits=0, pcHits=449, showPcHits=2057, likes=1, shares=24, comments=7, approvalStatus=1, publishedTime=Wed Aug 10 10:31:00 CST 2022, publishedTimeString=2022-07-15, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=FUNNYMAN, createdTime=Fri Aug 05 10:33:59 CST 2022, updatedBy=6459136, updatedName=艺玮, updatedTime=Sat Jan 06 11:35:25 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=血管紧张素转换酶抑制药_血管紧张素受体阻滞药联合钙通道阻滞剂单片复方制剂治疗原发性高血压中国专家共识.pdf)])
血管紧张素转换酶抑制药_血管紧张素受体阻滞药联合钙通道阻滞剂单片复方制剂治疗原发性高血压中国专家共识.pdf
下载请点击:
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2152056, encodeId=c90f215205696, content=缬沙坦比厄贝差那么一丢丢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Thu Aug 10 08:22:35 CST 2023, time=2023-08-10, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2152055, encodeId=94002152055b0, content=黄金搭配;希望上市厄贝沙坦150mg/氨氯地平5mg剂型,集采, beContent=null, objectType=guider, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Thu Aug 10 08:21:34 CST 2023, time=2023-08-10, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2107904, encodeId=d2e7210e9047a, content=指导临床用药, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Dec 28 20:32:28 CST 2022, time=2022-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2107903, encodeId=70a1210e903a4, content=下载认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Dec 28 20:32:04 CST 2022, time=2022-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2107902, encodeId=a592210e90247, content=学习受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Dec 28 20:31:52 CST 2022, time=2022-12-28, status=1, ipAttribution=新疆)]
    2023-08-10 forvalen 来自陕西省

    缬沙坦比厄贝差那么一丢丢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2152056, encodeId=c90f215205696, content=缬沙坦比厄贝差那么一丢丢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Thu Aug 10 08:22:35 CST 2023, time=2023-08-10, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2152055, encodeId=94002152055b0, content=黄金搭配;希望上市厄贝沙坦150mg/氨氯地平5mg剂型,集采, beContent=null, objectType=guider, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Thu Aug 10 08:21:34 CST 2023, time=2023-08-10, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2107904, encodeId=d2e7210e9047a, content=指导临床用药, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Dec 28 20:32:28 CST 2022, time=2022-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2107903, encodeId=70a1210e903a4, content=下载认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Dec 28 20:32:04 CST 2022, time=2022-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2107902, encodeId=a592210e90247, content=学习受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Dec 28 20:31:52 CST 2022, time=2022-12-28, status=1, ipAttribution=新疆)]
    2023-08-10 forvalen 来自陕西省

    黄金搭配;希望上市厄贝沙坦150mg/氨氯地平5mg剂型,集采

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2152056, encodeId=c90f215205696, content=缬沙坦比厄贝差那么一丢丢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Thu Aug 10 08:22:35 CST 2023, time=2023-08-10, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2152055, encodeId=94002152055b0, content=黄金搭配;希望上市厄贝沙坦150mg/氨氯地平5mg剂型,集采, beContent=null, objectType=guider, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Thu Aug 10 08:21:34 CST 2023, time=2023-08-10, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2107904, encodeId=d2e7210e9047a, content=指导临床用药, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Dec 28 20:32:28 CST 2022, time=2022-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2107903, encodeId=70a1210e903a4, content=下载认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Dec 28 20:32:04 CST 2022, time=2022-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2107902, encodeId=a592210e90247, content=学习受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Dec 28 20:31:52 CST 2022, time=2022-12-28, status=1, ipAttribution=新疆)]
    2022-12-28 delianjihui 来自新疆

    指导临床用药

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2152056, encodeId=c90f215205696, content=缬沙坦比厄贝差那么一丢丢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Thu Aug 10 08:22:35 CST 2023, time=2023-08-10, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2152055, encodeId=94002152055b0, content=黄金搭配;希望上市厄贝沙坦150mg/氨氯地平5mg剂型,集采, beContent=null, objectType=guider, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Thu Aug 10 08:21:34 CST 2023, time=2023-08-10, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2107904, encodeId=d2e7210e9047a, content=指导临床用药, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Dec 28 20:32:28 CST 2022, time=2022-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2107903, encodeId=70a1210e903a4, content=下载认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Dec 28 20:32:04 CST 2022, time=2022-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2107902, encodeId=a592210e90247, content=学习受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Dec 28 20:31:52 CST 2022, time=2022-12-28, status=1, ipAttribution=新疆)]
    2022-12-28 delianjihui 来自新疆

    下载认真学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2152056, encodeId=c90f215205696, content=缬沙坦比厄贝差那么一丢丢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Thu Aug 10 08:22:35 CST 2023, time=2023-08-10, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2152055, encodeId=94002152055b0, content=黄金搭配;希望上市厄贝沙坦150mg/氨氯地平5mg剂型,集采, beContent=null, objectType=guider, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Thu Aug 10 08:21:34 CST 2023, time=2023-08-10, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2107904, encodeId=d2e7210e9047a, content=指导临床用药, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Dec 28 20:32:28 CST 2022, time=2022-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2107903, encodeId=70a1210e903a4, content=下载认真学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Dec 28 20:32:04 CST 2022, time=2022-12-28, status=1, ipAttribution=新疆), GetPortalCommentsPageByObjectIdResponse(id=2107902, encodeId=a592210e90247, content=学习受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5281475204, createdName=delianjihui, createdTime=Wed Dec 28 20:31:52 CST 2022, time=2022-12-28, status=1, ipAttribution=新疆)]
    2022-12-28 delianjihui 来自新疆

    学习受益

    0